March 25, 2024 7:00 AM EDT
Regeneron Provides Update on Biologics License Application for Odronextamab
March 12, 2024 9:30 PM EDT
High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization
March 11, 2024 7:00 AM EDT
Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol
March 8, 2024 7:00 AM EST
EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet
February 23, 2024 1:00 AM EST
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation
February 21, 2024 7:00 AM EST
Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review
February 16, 2024 12:59 AM EST
Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
February 6, 2024 4:05 PM EST
Regeneron Announces Investor Conference Presentations
February 2, 2024 6:30 AM EST
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
February 2, 2024 6:00 AM EST